Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020094590 - 5,8-DIMETHYL-2-[2-(1-METHYL-4-PHENYL-1H-IMIDAZOL-2-YL)-ETHYL]-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE HEMIADIPATE

Publication Number WO/2020/094590
Publication Date 14.05.2020
International Application No. PCT/EP2019/080150
International Filing Date 05.11.2019
IPC
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/4985 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61P 25/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
CPC
A61K 9/1682
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1682Processes
A61P 25/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
C07B 2200/13
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
13Crystalline forms, e.g. polymorphs
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • H. LUNDBECK A/S [DK]/[DK]
Inventors
  • JENSEN, Anette, Frost
  • LYNGSØ, Lars, Ole
  • NIELSEN, Flemming, Elmelund
Priority Data
19189761.002.08.2019EP
PA20180082506.11.2018DK
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 5,8-DIMETHYL-2-[2-(1-METHYL-4-PHENYL-1H-IMIDAZOL-2-YL)-ETHYL]-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE HEMIADIPATE
(FR) HÉMIADIPATE DE 5,8-DIMÉTHYL-2-[2-(1-MÉTHYL-4-PHÉNYL-1H-IMIDAZOL-2-YL)-ÉTHYL]-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE
Abstract
(EN)
The present invention relates to 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]- [1,2,4]triazolo[1,5-a]pyrazine hemiadipate, which is non-hygroscopic. The present invention also relates to pharmaceutical compositions comprising 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)- ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate, as well as the use of 5,8-Dimethyl-2-[2-(1-methyl-4- phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate in therapy. The 5,8-Dimethyl- 2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate being depicted below. Formula (I).
(FR)
La présente invention concerne un hémiadipate de 5,8-diméthyl-2-[2-(1-méthyl-4-phényl-1H-imidazol-2-yl)-éthyl]- [1,2,4]triazolo[1,5-a]pyrazine, qui est non hygroscopique. La présente invention concerne également des compositions pharmaceutiques comprenant l'hémiadipate de 5,8-diméthyl-2-[2-(1-méthyl-4-phényl-1H-imidazol-2-yl)- éthyl]-[1,2,4]triazolo[1,5-a]pyrazine, ainsi que l'utilisation de l'hémiadipate de 5,8-diméthyl-2-[2-(1-méthyl-4- phényl-1H-imidazol-2-yl)-éthyl]-[1,2,4]triazolo[1,5-a]pyrazine en thérapie. L'hémiadipate de 5,8-diméthyl- 2-[2-(1-méthyl-4-phényl-1H-imidazol-2-yl)-éthyl]-[1,2,4]triazolo[1,5-a]pyrazine étant représenté ci-dessous. Formule (I).
Latest bibliographic data on file with the International Bureau